Skip to main content
An official website of the United States government

cemiplimab-rwlc

View Patient Information
A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab-rwlc binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.
Synonym:cemiplimab
cemiplimab RWLC
US brand name:Libtayo
Code name:REGN2810
Chemical structure:immunoglobulin G4, anti-(human programmed cell death protein 1) (human monoclonal REGN2810 heavy chain), disulfide with human monoclonal REGN2810 kappa-chain, dimer
Search NCI's Drug Dictionary